Metabolic Syndrome, Cardiovascular Risk and Insulin Resistance in Pediatric Survivors of Brain Tumors Treated with Radiation
This descriptive prevalence study will evaluate a group of brain tumor survivors (n ~80: 50 age ten years and over, 30 between ages five and nine) treated with radiation for components of the metabolic syndrome. They will be compared to a control group of survivors who did not receive cranial radiation (n ~100: 50 age ten years and over, 50 between ages five and nine).
Primary Endpoint is a diagnosis of metabolic syndrome (for patients age ten years and over) or concomitant cardiometabolic risk (patients age five to nine years).
Diagnostic criteria for metabolic syndrome include central obesity AND two of the four following: elevated triglycerides, low high density lipoprotein (HDL), insulin resistance as evidenced by elevated fasting glucose, and elevated blood pressure.
Diagnostic criteria for concomitant cardiometabolic risk are similar to those for metabolic syndrome, but are modified based on age-, gender-, and height-based percentiles. See protocol section 1.4.2.
1. Survivors of childhood brain tumors (age <18 at diagnosis)
2. Patients who are >1 year after completing therapy for their tumor
3. Group A (study population) will have received prior treatment with >20Gy cranial radiation therapy to the hypothalamus
4. Group B (control) will have had no cranial radiation therapy
5. Age at time of study: 5-20 years